Intraperitoneal chemotherapy for ovarian cancer: a question of feasibility?

被引:6
作者
Willemse, PHB [1 ]
de Vries, EGE [1 ]
机构
[1] Univ Groningen Hosp, Dept Med Oncol, NL-9700 RB Groningen, Netherlands
关键词
intraperitoneal chemotherapy; ovarian cancer; cisplatin; paclitaxel;
D O I
10.1016/S1368-7646(03)00061-X
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Increasing the tumor concentration of chemotherapeutic agents by local administration seems one logical approach to increase the efficacy of treatment. This approach is actively pursued in ovarian cancer, which allows local, intraperitoneal drug administration. In this commentary we put into perspective a recent study of Rothenberg et al. [J. Clin. Oncol. 21 (2003) 1313-1319] reporting on IP administration of a combination of cisplatin and paclitaxel. We argue that feasibility of IP administration of chemotherapy should not preclude its application. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:165 / 167
页数:3
相关论文
共 16 条
[1]
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].
Alberts, DS ;
Liu, PY ;
Hannigan, EV ;
OToole, R ;
Williams, SD ;
Young, JA ;
Franklin, EW ;
ClarkePearson, DL ;
Malviya, VK ;
DuBeshter, B ;
Adelson, MD ;
Hoskins, WJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955
[2]
Pharmacokinetic problems in peritoneal drug administration: Tissue penetration and surface exposure [J].
Dedrick, RL ;
Flessner, MF .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (07) :480-487
[3]
PHASE-II STUDY OF INTRAPERITONEAL CISPLATIN PLUS SYSTEMIC ETOPOSIDE AS 2ND-LINE TREATMENT IN PATIENTS WITH SMALL-VOLUME RESIDUAL OVARIAN-CANCER [J].
DEJONG, RS ;
WILLEMSE, PHB ;
BOONSTRA, H ;
DEVRIES, EGE ;
VANDERGRAAF, WTA ;
SLEIJFER, DT ;
VANDERZEE, AGJ ;
MULDER, NH .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (05) :709-713
[4]
Kinetic modeling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancer [J].
Hofstra, LS ;
Bos, AME ;
de Vries, EGE ;
van der Zee, AGJ ;
Willemsen, ATM ;
Rosing, H ;
Beijnen, JH ;
Mulder, NH ;
Aalders, JG ;
Willemse, PHB .
GYNECOLOGIC ONCOLOGY, 2002, 85 (03) :517-523
[5]
A COMPARISON OF INTRAVENOUS VERSUS INTRAPERITONEAL CHEMOTHERAPY FOR THE INITIAL TREATMENT OF OVARIAN-CANCER [J].
KIRMANI, S ;
BRALY, PS ;
MCCLAY, EF ;
SALTZSTEIN, SL ;
PLAXE, SC ;
KIM, S ;
CATES, C ;
HOWELL, SB .
GYNECOLOGIC ONCOLOGY, 1994, 54 (03) :338-344
[6]
PENETRATION OF CARBOPLATIN AND CISPLATIN INTO RAT PERITONEAL TUMOR NODULES AFTER INTRAPERITONEAL CHEMOTHERAPY [J].
LOS, G ;
VERDEGAAL, EME ;
MUTSAERS, PHA ;
MCVIE, JG .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1991, 28 (03) :159-165
[7]
IMPACT ON SURVIVAL OF SURGICALLY DEFINED FAVORABLE RESPONSES TO SALVAGE INTRAPERITONEAL CHEMOTHERAPY IN SMALL-VOLUME RESIDUAL OVARIAN-CANCER [J].
MARKMAN, M ;
REICHMAN, B ;
HAKES, T ;
LEWIS, JL ;
JONES, W ;
RUBIN, S ;
BARAKAT, R ;
CURTIN, J ;
ALMADRONES, L ;
HOSKINS, W .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (09) :1479-1484
[8]
Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group [J].
Markman, M ;
Bundy, BN ;
Alberts, DS ;
Fowler, JM ;
Clark-Pearson, DL ;
Carson, LF ;
Wadler, S ;
Sickel, J .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (04) :1001-1007
[9]
LOW COMPLICATION RATE DURING INTRAPERITONEAL THERAPY THROUGH A TOTALLY IMPLANTED PERITONEAL ACCESS PORT IN PATIENTS WITH OVARIAN-CANCER [J].
NANNINGA, AG ;
WILLEMSE, PHB ;
BOONSTRA, H ;
DEVRIES, EGE .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1992, 2 (02) :107-110
[10]
OZOLS RF, 1979, CANCER RES, V39, P3209